A Natural Solution: Why Should FDA Define “Natural” Foods?

Posted on September 2014 by Laura Brown, FDLI, Editor

For Release:  September 24, 2014 Contact: Laura Brown, Editor, FDLI  Phone: (202) 222-0894  E-Mail: lab@fdli.org    A Natural Solution: Why Should FDA Define “Natural...read more

GRAS, or generally recognized as safe, is an exemption that allows ingredients that are considered to be GRAS for their intended use to be exempt from FDA premarket review when added to food. The G...read more

FDLI Names New President and Chief Executive Officer

Posted on May 2014 by Michael Levin‐Epstein

FDLI Names New President and Chief Executive Officer Amy Comstock Rick to lead organization effective August 25th The Food and Drug Law Institute (FDLI) announces the selection of Amy Comstock Ric...read more

The Food and Drug Law Institute, the premier educational organization in the field of food and drug law, announced today that President and Chief Executive Officer Susan C. Winckler will step down ...read more

“Ravioli Trees and Tortellini Bushes: What Should Courts Expect from the Reasonable Consumer When it Comes to ‘Natural’ Claims?” is the timely topic addressed by John E. Vil...read more

The Food and Drug Law Institute To Honor Axelrad, Gibbs, Holcombe, Kingham

Posted on December 2013 by Michel Levin-Epstein, Editor-in-Chief, FDLI

Honorees Will Receive Distinguished Service and Leadership Awards at Holiday Reception December 10 December 5, Washington, DC -- The Food and Drug Law Institute will honor four outstanding food and...read more

“How Should FDA Implement a More Rational and Workable Approach to  Regulating Tobacco, Nicotine, and Alternative Harm Reduction Products?” is the topic addressed by Frank Dukes, P...read more

Constitutionality of State Biosimilar Substitution Bills Is Focus of New FDLI Food and Drug Law Policy Forum

Posted on September 2013 by Michael Levin-Epstein, Editor-in-Chief, FDLI

“Do Pending State Biosimilar Substitution Bills Violate State Constitutional Law Principles of Non-Delegation and Incorporation by Reference?” is the timely topic addressed by Neal Park...read more

Genetically-Engineered Salmon Is Focus of Two New FDLI Food and Drug Law Policy Forums

Posted on August 2013 by Michael Levin-Epstein, Editor-in-Chief, FDLI

The July 24th release is structured in a way new for Policy Forum: a point (by Timothy Schwab) and counterpoint (by Alison L. Van Eenennaam, William M. Muir and Eric M. Hallerman) presented at the ...read more

read more